SCHEMBL22096035

SCHEMBL22096035

O=C(O)c1nonc1NCn1nnnc1COc1ccccc1

nearest known ligand 0.72

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
STAT5B P51692 4/20 0.72
KDM4C Q9H3R0 1/20 0.56
PKM P14618 2/20 0.43
HTT P42858 2/20 0.43
NLRP3 Q96P20 1/20 0.43
ALDH1A1 P00352 6/20 0.38
GAA P10253 1/20 0.38
TSHR P16473 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
LMNA P02545 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
THRB P10828 1/20 0.35
USP2 O75604 1/20 0.35
DOT1L Q8TEK3 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22096036 0.90 STAT5B (0.69) STAT5BKDM4CPKMHTTNLRP3
SCHEMBL22096039 0.86 STAT5B (0.77) STAT5BKDM4CPKMHTTALDH1A1
SCHEMBL22096012 0.84 STAT5B (0.83) STAT5BKDM4CALDH1A1
SCHEMBL22096037 0.84 STAT5B (0.73) STAT5BKDM4CALDH1A1GAATSHR
SCHEMBL22096030 0.83 STAT5B (0.82) STAT5BALDH1A1GAATSHRSMN1; SMN2
SCHEMBL22096031 0.81 STAT5B (0.78) STAT5BALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL22096032 0.81 STAT5B (0.78) STAT5BHTTALDH1A1SMN1; SMN2KMT2A
SCHEMBL20047849 0.81 STAT5B (0.78) STAT5BALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL22096011 0.80 STAT5B (0.88) STAT5BALDH1A1
SCHEMBL22096016 0.80 STAT5B (0.81) STAT5BHTTALDH1A1TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10683286-B2 Furazan-3-carboxylic acid derivatives and use thereof in treatment of cancer FREIE UNIVERSITAET BERLIN (DE) 2020-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10683286-B2 Furazan-3-carboxylic acid derivatives and use thereof in treatment of cancer FLT3, MCL1, MYD88 STAT5B 59/4885KDM4C 1031/4885PKM 3449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.